Showing results (121-130 of 210) with videos related to
Sort By:
Pageof 21
European Journal of Cancer (Oxford, England : 1990)|May 18, 2016
Survival of elderly patients with multiple myeloma-Effect of upfront autologous stem cell transplantationMaximilian Merz, Lina Jansen, Felipe A Castro, et al.Cancer|July 27, 2021
Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 studySagar Lonial, Hans C Lee, Ashraf Badros, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2022
Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III TrialPieter Sonneveld, Asher Chanan-Khan, Katja Weisel, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2018
Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II TrialMeletios Dimopoulos, Katja Weisel, Niels W C J van de Donk, et al.Frontiers in Immunology|November 30, 2023
RNA-sequencing based first choice of treatment and determination of risk in multiple myelomaMartina Emde-Rajaratnam, Susanne Beck, Vladimir Benes, et al.The Oncologist|April 1, 2026
Time dependent outcomes modeling in a real-world analysis of the molecular tumor board at university cancer center Hamburg (2016-2022)Janna-Lisa Velthaus-Rusik, Jan Frederic Weller, Melisa Hoshaber, et al.Future Oncology (London, England)|March 1, 2019
INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myelomaCaitlin Costello, Faith E Davies, Gordon Cook, et al.Leukemia & Lymphoma|September 27, 2019
Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general populationHeinz Ludwig, Wolfram Pönisch, Stefan Knop, et al.Cancer|April 17, 2024
Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myelomaAttaya Suvannasankha, Nizar Bahlis, Suzanne Trudel, et al.Haematologica|June 22, 2019
Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studiesMaria-Victoria Mateos, Andrew Spencer, Ajay K Nooka, et al.Pageof 21